| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10343
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2800-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2830-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2830-42 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-861
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-86 |
| filingDate |
2002-06-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_19acd71060ccbdbeded8f2e7b4dd1581
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_01b75c18a04845dbbb3cb2d8b8f1ea4a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e9da28f08ad5cc958572f0fa8a9cd81a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dadb1d5ec4aef4e871c15dc8a5b6dfd0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7ff9e9f2aa8145d4368358f20b1f311e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_20bf6fdb1f2c2dcb6f44844d8f156fbe
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_202fb3869eace30d40e786070457c098
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5134acb72788f4d84f8eb71581b9595b |
| publicationDate |
2003-05-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2003100116-A1 |
| titleOfInvention |
Canine adenovirus vectors for the transfer of genes in targeted cells |
| abstract |
Recombinant Canine Adenovirus (CAV) vectors based on CAV-2 strain Toronto in which the CAV-2 E1 region has been deleted are described herein. Methods for the preparation of recombinant vectors include the use of transcomplementation cell lines which are specifically employed to reduce the likelihood of generating replication competent CAV-2 during propagation of the vectors. The resultant replication-defective, E1-deficient CAV preparations are highly desirable for the transfer of nucleic acid sequences in vitro and in vivo. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10626414-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11261464-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10329586-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10619169-B2 |
| priorityDate |
1999-12-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |